Clicky

The Global Ministerial Mental Health Summit

GlobalMHSummit.com

Info

ADHD and Ethnicity: What Actually Matters for Diagnosis

by

Ethnicity is not a reliable way to decide whether you or your child has ADHD. The useful question is whether attention, impulsivity, or activity patterns began in childhood, show up in more than one part of life, and are making school, work, relationships, or daily tasks harder.

Does one ethnicity have ADHD more often?

No ethnicity should be treated as “most likely” to have ADHD. ADHD assessment is about a person’s history and how symptoms affect their life, not a racial or ethnic label.

Race and ethnicity can still matter in a different way: access to assessment and support is not equal. A current ClinicalTrials.gov ADHD access study, planned for 350 participants, is developing school-based support for children in low-income and racial and ethnic minority communities. Its focus is practical barriers such as time, transportation, stigma, and limited school resources.

If you are asking because someone’s struggles have been dismissed or explained away, start with the pattern itself. Write down when the problems began, where they happen, and what they interfere with. That gives a clinician much more to work with than a demographic category.

What makes ADHD different from ordinary distraction?

Being distracted, tired, stressed, or overloaded does not automatically mean ADHD. In a University of Utah discussion, psychiatrist Rachel Weir explains that ADHD begins in childhood; for a diagnosis, symptoms must have been present before age 12. The pattern can continue into adulthood even when nobody recognized it at school.

The key issue is impact. Trouble focusing becomes more important when it repeatedly affects work, school, home life, relationships, organization, driving, or other everyday responsibilities. A one-time online questionnaire cannot settle that question. The University of Utah’s adult ADHD guide describes a fuller assessment that considers childhood history, reports from people who know you, daily functioning, and other possible causes.

What can look like ADHD?

Anxiety, depression, poor sleep, alcohol use, and marijuana use can all make concentration feel thin or scattered. The Utah discussion also notes that a new attention problem beginning for the first time in your 30s, 40s, or 50s calls for a careful look at other explanations rather than an assumption that it is ADHD.

This matters because the answer should fit the problem. If anxiety keeps your mind racing, sleep leaves you foggy, or low mood drains your focus, naming that pattern accurately is more useful than chasing a label. Our guide to common mental health disorders can help you put related symptoms into context.

Was ADHD once called ADD?

Yes. “ADD,” or attention deficit disorder, is still a term many people use, especially when they do not feel physically hyperactive. Current clinical language uses ADHD and may describe a predominantly inattentive presentation, a predominantly hyperactive presentation, or a combined presentation. Inattention can be easy to miss in childhood when a person is quiet, daydreams, or works hard to hide the struggle.

Is ADHD inherited from your mother or father?

This page cannot tell you that ADHD comes from one parent rather than the other. Family history can be useful information to share during an assessment, but it does not replace looking at your own childhood pattern and current functioning.

Is ADHD linked to high IQ?

High ability does not rule ADHD in or out. A person can do well in some settings and still find planning, starting tasks, organizing time, or keeping attention on uninteresting work difficult. That is why a thoughtful assessment looks beyond a single strength, score, or self-screening result.

Can food, color, or a Bible reference diagnose ADHD?

No. Food preferences, a favorite color, and religious references are not part of an ADHD assessment. If you are trying to improve everyday focus while you sort out what is going on, practical routines can help: regular sleep, lists, calendars, and a quieter place for demanding work. For more non-medication approaches, see ADHD management beyond medication.

Before you decide what to do next

  • Ask whether the pattern was present before age 12.
  • Notice whether it affects more than one setting, not only one stressful season at work or school.
  • Bring up sleep, anxiety, mood, alcohol, cannabis, and medications that may affect concentration.
  • If you take or are considering stimulants or nootropic products, review possible concerns in our stimulant medication interactions guide.

By GlobalMHSummit.com Research Team

CBD Trials: Registered Outcomes and Published Results

by

By GlobalMHSummit.com Research Team. Sources checked October 6, 2026.

You can compare a trial's registry record with its published paper, and doing so shows you something a headline never will: which outcomes the researchers said they would measure, and which ones the paper actually reports. This guide does that for one well-documented example, a Colorado study of cannabis flower and anxiety. It is a lesson in reading research, not an answer about whether CBD works.

The short version for this example: the registry record listed three primary outcomes in April 2018, and the paper reports two of them. Part of the paper's CBD finding, the short-term tension and paranoia results, rests on mood measures that the registry record does not name. That does not mean anything improper happened. It means a careful reader has questions to ask, and this page shows you where to find the answers.

What we compared, and what kind of study it is

The registry record is NCT03491384 on ClinicalTrials.gov, sponsored by the University of Colorado, Boulder. The paper is Bidwell et al., Cannabis and Cannabinoid Research, 2024 (PubMed listing), which cites that registry number.

The two documents describe the study design differently, and the differences matter:

  • The registry record lists the study type as observational, with a cohort model and a prospective time perspective, not as an interventional clinical trial. Source: current record. ClinicalTrials.gov's own guide to reading a record explains that observational studies are those where participants are not assigned an intervention by the researchers.
  • The paper calls its design quasi-experimental, with a nonequivalent control group. Adults who chose to use cannabis were randomly assigned to one of three legal-market cannabis flower products (THC-dominant, about equal THC and CBD, or CBD-dominant), while a comparison group of non-users was self-selected. There was no placebo, and participants knew which product they bought. Source: paper, Methods and Limitations.
  • The paper uses several labels for itself: “quasi-experimental” in the title, “randomized” in the discussion, and “quasirandomized” in the conclusion. The accurate summary is that product assignment among users was randomized, but this was not a placebo-controlled randomized trial.

This is also legal-market cannabis flower bought by participants in Colorado, not CBD gummies, oils, or isolate products. The CBD-dominant product in the paper was about 24% CBD with under 1% THC flower. Source: paper, Abstract.

Registration-to-paper outcome comparison

The record's History tab shows nine versions. Version 1 was submitted 2018-04-05 and listed three primary outcomes. The change list for versions 2 through 7 shows no edits to outcome measures, and we read version 7 (2023-10-13) to confirm its outcomes match version 1. The changes to outcome measures appear in the versions submitted 2024-12-03 and 2025-08-25, both after the paper's January 2024 online publication. Source: record history; version 1; version 7.

Here is the comparison, outcome by outcome. Each item gives what the registry said and what the paper reports.

Registered primary outcomes

  • Anxiety on the DASS-21 questionnaire. Registered in 2018 as a change in anxiety and negative affect across all three DASS subscales, to be tested against blood THC and CBD levels. The current record narrows the primary outcome to the anxiety subscale. The paper reports all three subscales. All groups, including non-users, improved over four weeks. Among cannabis users, the anxiety score fell more in the CBD-dominant group than in the THC-dominant group, a difference of about 1 point (reported p=0.02) on a scale the registry describes as running 0 to 42. When non-users were included, the paper reports no significant group or group-by-time effect on any subscale. The paper analyzes results by assigned product group; in the text we read, we did not see DASS change modeled against blood levels. Source: paper, Results.
  • Inflammation (blood cytokine levels). Registered as a primary outcome from version 1 onward, and the registry's Results tab lists it among the posted outcomes. The paper's text does not mention cytokines or inflammation. We did not open the registry's posted data for this outcome or the paper's supplementary tables, so we cannot say what the data show. Source: results tab.
  • Patient Global Impression of Change (PGIC), a one-item rating of how much anxiety has changed. Registered as primary. The paper reports it. All groups reported improvement, and the three cannabis groups reported more improvement than non-users but did not differ from each other. The authors note that expectancy may explain the user versus non-user gap, since non-users made no study-related change. One detail differs: the current record says PGIC was given only once, at four weeks, while the paper says it was measured at two and four weeks. Source: paper, Methods and Discussion.

Measures the paper emphasizes that the registry does not name

  • Profile of Mood States (tension, paranoia, elation), measured right after use. The paper's acute finding, that tension fell after CBD-dominant use but not after the other products, comes from this measure. The registry record versions we read do not list it by name. In versions 1 through 7, a secondary outcome called Depression and Mood refers generally to self-reported mood states, so whether this counts as covered is a judgment call. The protocol document posted on the record (version 21, dated June 1, 2023) does describe this instrument as part of data collection. Source: protocol PDF.
  • Addiction Research Center Inventory (subjective drug effects) and blood cannabinoid levels after use. Reported in the paper as acute outcomes. The protocol describes the inventory; the registry versions we read do not name it as an outcome.

Registered secondary outcomes the paper does not report

  • The registry lists cognitive testing, a negative-affect induction task, balance and motor testing, physical activity, and general health and wellbeing among secondary outcomes. The paper does not report them, although it states that it reports all measures in the study. The record's publication list includes later papers from the same study, and their titles suggest they cover some of these outcomes. We have not read those papers. Source: record, Study Plan and Publications.

What this comparison can and cannot tell you

It can show you whether a paper's headline result comes from an outcome the researchers named in advance, whether the registered design matches the published one, and whether outcomes disappeared or appeared along the way. It is a transparency check. A mismatch is not automatically a problem: one study can produce several papers, and registry records can be updated over time. It is a prompt to ask questions.

It cannot tell you whether CBD reduces anxiety. For this example specifically:

  • With no placebo group and participants who knew their product, expectations could shape self-reported results. The authors say so in their limitations section.
  • The non-user comparison group was self-selected, so the groups may differ in ways the study did not measure.
  • Use was self-directed (“ad libitum”), so doses varied, and long-term exposure was self-reported.
  • The study tested cannabis flower in adults who wanted to use cannabis for anxiety (the registry lists ages 21 to 70). It says nothing about gummies, oils, or isolates, or about people outside that group.
  • A registry listing is not an endorsement. ClinicalTrials.gov states that the U.S. government does not review or approve the safety and science of all studies listed there, and this record lists no FDA-regulated drug product. A seller citing a registry number has not shown that its product works. Source: record banner and Drug and device information.

What is still missing or unresolved

  • Timing. The paper says recruitment began in March 2017. The registry record was first submitted on 2018-02-28 and first posted on 2018-04-09, and the paper calls the study preregistered. The documents do not explain the gap, which could reflect screening versus formal study start. Only the authors can say.
  • Enrollment. The record lists 210 (estimated) in 2018, 503 (actual) in the October 2023 version, and 361 (actual) now. The paper analyzed 300 people. We did not find the reasons in the record.
  • The inflammation outcome. Where, if anywhere, those results are published is not clear from the paper.
  • The PGIC timing difference between the record and the paper.
  • Supplementary tables and the registry's posted result tables were not reviewed for this page.

How to run this check on any CBD study

  1. Find the registry number (it starts with NCT) in the paper's abstract or methods. If there is no number, that is worth asking about.
  2. On ClinicalTrials.gov, check Study Type. Interventional and observational studies answer different questions.
  3. Read the Primary Outcome Measures, which the site describes as the most important measures. See the how-to-read guide for what each section means.
  4. Open the Record History tab and read the earliest version. Note the date and whether outcomes changed later, and whether the changes came before or after the paper.
  5. List which registered outcomes the paper reports, which it leaves out, and which new ones it adds. Then ask whether the paper's main claim rests on a registered outcome.

For a broader checklist, see our guide to reading mental-health research headlines and our explainer on which measure a well-being study used.

Who to ask next

If you have anxiety symptoms or are wondering about a CBD or cannabis product for them, that is a conversation for a licensed clinician. Please do not start, stop, or change any medicine on the basis of a study summary. If you take prescription medicines, a pharmacist or prescriber can check for interactions; our questions to ask a pharmacist and appointment preparation guide can help you get ready. Questions about whether a product is lawful to sell or what its label may claim belong with the relevant regulator, such as the FDA or your state agency. Questions about a specific trial's missing outcomes are best sent to the paper's corresponding author or the journal; ClinicalTrials.gov does not list a study contact for completed studies, and this one lists none.

Sources

  1. ClinicalTrials.gov record NCT03491384, current version (last update posted 2025-08-27). Checked October 6, 2026.
  2. Record version 1 (submitted 2018-04-05) and version 7 (submitted 2023-10-13). Checked October 6, 2026.
  3. Record results tab. Checked October 6, 2026.
  4. ClinicalTrials.gov, How to Read a Study Record. Checked October 6, 2026.
  5. Bidwell LC, Martin-Willett R, Skrzynski C, et al. Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-Experimental ad libitum Use Study. Cannabis Cannabinoid Res. 2024;9(4):1015-1027. doi:10.1089/can.2023.0187. Full text; PubMed. Checked October 6, 2026.
  6. Study protocol and statistical analysis plan, version 21 (June 1, 2023), posted on the record. Checked October 6, 2026.

This article is educational and is not medical advice. It does not diagnose or treat any condition, recommend any product, or suggest starting or stopping any medicine. Global MH Summit (GlobalMHSummit.com) is an independent publication. It is not affiliated with any university, hospital, clinic, government agency, or event organizer, and it does not provide medical care. See our medical disclaimer and editorial standards.

How to Make a Safety Plan for a Difficult Mental-Health Day

by

A safety plan for a difficult day is a short written list you make while you are steady, so you are not figuring everything out when you are overwhelmed. Mostly it comes down to three things: who you will contact, what practical help you will line up, and when you will move to urgent help. It does not treat or diagnose anything, and it does not replace care from a licensed professional.

If you need help right now

Do not wait to finish a plan. Use one of these first:

These are United States services. If you are elsewhere, use your local emergency number and ask a local health provider or health service what crisis options exist where you live.

What a difficult-day plan is for

Think of it as an organized address book plus a few practical decisions made ahead of time. It helps you answer “who do I call, who can help with the practical stuff, and when do I use urgent services?” without having to think hard in the moment.

This article does not claim that having a plan changes outcomes, and it does not give treatment advice. Questions about therapy or medication belong with a licensed provider. NIMH specifically says not to stop treatment without talking to your health care provider first.

Your personal support-and-contact worksheet

Copy this into a notes app, a document, or onto paper. Keep it somewhere you can reach quickly, and tell someone you trust where it is. Blanks you cannot fill yet are fine. Leave them and come back.

Part 1: People I can contact

  • Someone I can text or call: ______ (phone: ______)
  • Someone who could come over or stay with me: ______ (phone: ______)
  • Someone who could handle a practical task for me, such as a ride or errand: ______ (phone: ______)
  • Have I asked each of these people if they are willing to be on my list? Yes / No

Part 2: My care and support contacts

NIMH describes several places to find or reach care. Fill in whichever apply to you:

  • Primary care provider: ______ (phone and hours: ______). NIMH notes a primary care provider can do an initial mental health screening and refer you to a mental health professional.
  • Therapist, psychiatrist, or other mental health professional: ______ (phone and after-hours instructions: ______)
  • Employee assistance program, if my employer offers one: ______. NIMH describes it as a free, confidential service that the company pays for.
  • School or college health center, if I am a student: ______
  • My health insurance company's member line, for finding participating providers: ______

Part 3: Practical supports for a hard day

These are logistics, not treatment. Decide them ahead of time so you do not have to improvise.

  • A place I can go where I will not be alone: ______
  • Who could cover work, school, childcare, or pet care if I need to step back: ______
  • How I would get somewhere if I could not drive: ______
  • A written list of my current medicines and my providers' names, to hand to anyone helping me. Where it is kept: ______

Part 4: Urgent-help options

  • Call or text 988, or chat online (United States): saved in my phone? Yes / No
  • Emergency number where I live: ______
  • Nearest emergency room and how I would get there: ______
  • If I am a veteran: Veterans Crisis Line (988, then press 1; text 838255)
  • If I am outside the United States, my local crisis service: ______

Part 5: My line for moving to urgent help

Write one or two sentences in your own words about when you will stop working through your contact list and use urgent help instead. For example: “If I think I might hurt myself or can't stay safe, I will call 988 or my local emergency number right away.” If you are in a life-threatening situation, call 911 or your local emergency number immediately.

  • My line: ______

Part 6: Questions for a provider

If you are looking for a new provider, NIMH suggests preparing questions in advance. Its examples include:

  • What experience do you have treating someone with my issue?
  • How do you usually treat someone with my issue?
  • How long do you expect treatment to last?
  • Do you accept my insurance?
  • How much will treatment cost?

NIMH adds that treatment works best when you have a good relationship with your provider, and that it is reasonable to raise concerns or look for a different provider or approach.

Who should talk to a professional

If you are having thoughts of suicide, use 988 or emergency services as described above. For anything short of an emergency, NIMH says that people who are struggling emotionally or have concerns about their mental health have ways to get help, and it names a primary care provider as one starting point. A plan on paper can help you prepare for that conversation, but it is not a replacement for it.

If you are helping someone else

You can use the same worksheet as a conversation guide, but the person it belongs to should fill it in. The 988 Lifeline says people can contact it for help with a friend or loved one. NIMH also publishes a fact sheet of action steps for helping someone who is having thoughts of suicide.

Limits of this article

  • It is general information, not medical advice. See our Medical Disclaimer and Editorial Standards.
  • The services listed are United States services. Availability elsewhere will differ.
  • Phone numbers and services can change. Check them against the official pages below before you rely on them.
  • This article comes from an editorial team and does not claim review or authorship by a clinician.

Sources

  1. National Institute of Mental Health, “Help for Mental Illnesses” (page lists last reviewed April 2026; checked October 6, 2026)
  2. 988 Suicide & Crisis Lifeline (checked October 6, 2026)
  3. National Institute of Mental Health, “5 Action Steps to Help Someone Having Thoughts of Suicide” (checked October 6, 2026; cited only for the existence and topic of this fact sheet)

By GlobalMHSummit.com Research Team

What to Bring to a First Therapy Consultation

by

For a first therapy consultation, bring a short written list: what you have been noticing and when it started, what you hope to get from therapy, your questions for the provider, everything you take (including supplements), any family mental health history, and your insurance details. That list is our summary of guidance from the National Institute of Mental Health (NIMH), which says that preparing a list of questions can help you decide whether a provider is a good fit for you.

If you or someone you know is in emotional distress or thinking about suicide, call or text 988 or chat online to reach the 988 Suicide & Crisis Lifeline, which offers 24-hour, confidential support. In a life-threatening situation, call 911 or go to the nearest emergency room.

A First-Visit Preparation List

Copy this into a notes app or onto paper. Use your own words. You are collecting observations, not naming a condition.

  1. What I have noticed. NIMH advises describing your symptoms and being specific about when they started, how severe they are, and how often they occur. Add major stressors or recent life changes that might be making things worse.
  2. What I hope to get from this. This one is our suggestion, not an NIMH requirement. Writing down a goal, such as understanding what is going on, learning coping skills, or finding out whether treatment makes sense, can help the conversation stay on track. It is fine if the goal is “I'm not sure yet.”
  3. My questions for the provider. NIMH lists these examples: What experience do you have treating someone with my issue? How do you usually treat someone with my issue? How long do you expect treatment to last? Do you accept my insurance? How much will treatment cost?
  4. Everything I take. NIMH says to tell your provider about all medications, including over-the-counter drugs, herbal remedies, vitamins, and supplements. We suggest writing the name, the amount on the label, and how often you take each one.
  5. Family mental health history. NIMH notes that certain mental illnesses tend to run in families, and that knowing your family history can help a provider look for early warning signs. Write down what you know.
  6. Insurance and cost details. If you have health insurance, NIMH says a representative of your insurance company will know which local providers your plan covers. Have your plan information on hand.
  7. Someone to come with me (optional). NIMH says a friend or relative can give support, help you take notes, and help you remember what was discussed. Some people prefer to meet alone first and have that person join later.
  8. Before I leave. This one is also our suggestion. Write down the agreed next step, who to contact if things change, and when the follow-up is.

Is This Provider a Good Fit?

A first consultation is also your chance to see whether the provider suits you. NIMH states that treatment works best when you have a good relationship with your mental health professional. If you have concerns about your treatment, or feel it is not helping, NIMH says to talk with your provider, and that in some cases you may wish to find a different provider or another type of treatment.

NIMH also notes that there is no one-size-fits-all treatment, and that finding what works may take talking with more than one provider.

Privacy: A Question Worth Asking

NIMH says discussions between you and a health care provider are private and cannot be shared with anyone without your expressed permission. Privacy rules and their exceptions can vary by provider, setting, and location, so it is reasonable to ask at the start what is and is not kept private in that specific setting.

Where to Find a Provider

NIMH's Help for Mental Illnesses page says treatment usually includes therapy (virtual or in person), medication, or a combination of the two. It lists several ways to find a provider:

  • Primary care provider. They can do an initial mental health screening and refer you to a mental health professional such as a social worker, psychologist, or psychiatrist.
  • Federal resources. These include the SAMHSA helpline and online locator for mental health services at findtreatment.gov.
  • State and county agencies. Your local health services department website is a good place to start.
  • Insurance companies. Your insurer may have an app or online database of participating providers.
  • Universities and colleges. Students may have access to mental health services through the school's health center.
  • Employee assistance. Ask your employer's human resources department whether there is an Employee Assistance Program (EAP), which NIMH describes as a free and confidential service paid for by your company.

When to Seek Professional Help

NIMH says that if you or someone you know is struggling emotionally or has concerns about their mental health, there are ways to get help. If you are already in treatment, NIMH's guidance is not to stop treatment without talking to your health care provider.

What to Read Next

For a general worksheet you can use before any mental health appointment, see How to Prepare for a Mental-Health Appointment After Seeing a Supplement Ad. For help deciding what you want out of a conversation and what happens afterward, see Preparing for a Mental Health Conversation.

What This Article Can't Tell You

This article does not recommend any provider, product, or treatment, and it can't tell you what is causing your symptoms or what care suits you. NIMH's tips are written for talking with a health care provider about mental health in general. We did not find a government source describing what happens in a first therapy session, so this article does not describe one. Ask the provider what to expect. NIMH describes itself as a research funding agency that cannot provide medical advice or provider referrals, and the same limit applies here. Those answers belong to a qualified professional who evaluates you. See our Medical Disclaimer and Editorial Standards.

Sources checked October 6, 2026: National Institute of Mental Health, “Help for Mental Illnesses” (last reviewed April 2026); National Institute of Mental Health, “Tips for Talking With a Health Care Provider About Your Mental Health“; 988 Suicide & Crisis Lifeline.

By GlobalMHSummit.com Research Team

Reading Mental-Health Research Headlines: A Plain-Language Evidence Checklist

by

By GlobalMHSummit.com Research Team

Short answer: a study finding describes what researchers saw in a specific group of people, under specific conditions, over a specific stretch of time. A treatment promise says what will happen to you. Headlines often slide from the first to the second without anything in the study changing. This page gives you a 10-question checklist to catch that slide before it shapes a decision about your health.

If you are in crisis or thinking about suicide, call or text 988 or start a chat online to reach a trained crisis counselor. In a life-threatening situation, call 911 or go to the nearest emergency room. (NIMH, Help for Mental Illnesses, checked October 6, 2026.)

Why a finding is not a promise

The National Library of Medicine's MedlinePlus puts the problem plainly: what you hear about a study may not explain how it fits into the bigger picture. Studies can seem to disagree because they were designed differently or asked different questions. Some are very small and need follow-up studies to confirm them, and news stories about those small studies may not say so (MedlinePlus, Understanding Medical Research).

That is why this checklist keeps two things apart. A finding is a result: this group, this measure, this time frame. A promise is a prediction about you. The distance between them is filled by the questions below.

The 10-question headline checklist

Run these on any mental-health research headline before you share it, act on it, or change anything because of it. Most of the questions come from MedlinePlus's list for evaluating medical findings: animals or people, similarity to you, size, length, type of study, side effects, comparison with earlier research, funding, and who is reporting. Question 6 is our plain-language restatement of how randomized trials work, and question 10 is our own.

  1. Was the study in animals or in people? MedlinePlus notes that results in animals may not carry over to humans. If the headline never says who or what was studied, find out before you believe it.
  2. Were the people studied like you? Age, race, and sex can matter. A result in one group may not apply to another.
  3. How big was the study? Larger studies may get more reliable results than smaller ones. A small study can be a useful first step, but it is rarely the last word.
  4. How long did it last? MedlinePlus notes that studies testing medicines need to be long enough to show long-term benefits or risks. A study that ended early may not show either.
  5. What kind of study was it? MedlinePlus says clinical trials, especially randomized controlled trials, give the clearest information about whether a treatment is effective and safe in humans. In those trials, participants are randomly divided into groups that get different treatments, which helps prevent bias. NIMH describes clinical trials as the primary way researchers determine whether a new treatment is safe and effective in people (NIMH, Clinical Trials). A study of another kind may still be valuable, but it answers a different question.
  6. Compared with what? In plain terms: “people improved” means little without knowing what the comparison group received. Look for words like “randomized,” “control,” or “comparison group.”
  7. What were the side effects, and how common were they? A headline about benefit that skips harms is only half a finding.
  8. Does it match earlier research? If a new study differs from earlier ones, MedlinePlus says more studies would be needed to confirm the new result. NCCIH adds that when researchers combine many studies in a systematic review or meta-analysis and they point the same way, that helps show the results are reliable (NCCIH, Know the Science: Types of Research).
  9. Who paid for it, and who is reporting it? MedlinePlus points out that funders sometimes profit if a study turns out a certain way, and that whoever reports the results may have a bias. This does not make a study wrong. It tells you what to double-check.
  10. Does the headline's verb match the study? This one is our own reading, not a sourced rule. Words like “linked to” or “may” describe a pattern or a possibility. Words like “treats,” “cures,” or “works” promise an outcome. If the verb in the headline is stronger than anything in questions 1 through 9, treat the headline as a promise the study has not made.

A quick illustration

This is an invented example, not a real study. Imagine a headline: “New study shows daily habit reduces anxiety.” Run the checklist. If the article never says whether participants were people or mice, how many there were, how long it lasted, or what the comparison group did, the headline has a finding-shaped hole in it. If you can answer most of the ten questions and they hold up, you have a stronger basis for a conversation with a health professional. Even then, you have a finding about a group, not a promise about you.

Go to the source when you can

NCCIH notes that journal articles often become the source material for news stories, and that going to the source, such as the study in a scientific journal, is important for finding reliable information. It also acknowledges that finding and interpreting those studies can be challenging. Its Know the Science guide walks through the parts of a journal article, including the abstract, methods, and results (NCCIH, How To Make Sense of a Scientific Journal Article). Our own suggestion: if a news story does not name the journal, the researchers, or the year, try to find them, and hold the claim more loosely until you do.

What this checklist cannot do

  • It cannot tell you whether a study is good. It can only help you see what the study did and did not do.
  • It cannot tell you whether a treatment or product is right for you, safe with your other medicines, or worth your money.
  • It cannot diagnose anything. Reading about symptoms in a headline is not the same as an evaluation.
  • Even well-run studies describe groups of people, not you.

Who should talk with a professional, and what to do next

Talk with a health care provider if a headline has made you wonder about your own mood, thinking, sleep, or stress. This applies especially if those experiences are lasting, getting worse, or getting in the way of daily life. NIMH says a primary care provider can perform an initial mental health screening and refer you to a mental health professional, and that treatment for mental illnesses usually includes therapy, medication, or a combination of the two. NIMH describes itself as a research funding agency and says it cannot provide medical advice or provider referrals (NIMH, Help for Mental Illnesses).

If you already take prescribed treatment, NIMH's guidance is not to stop treatment without talking to your health care provider. A headline is not a reason to change a prescription.

If you are in distress or having thoughts of suicide, the 988 Suicide & Crisis Lifeline says it is available 24/7/365, and conversations are free and confidential. You can call, text, or chat.

A practical next step: pick one headline you have seen recently, run the ten questions, and write down any you could not answer. Bring that note, along with what you are actually experiencing, to your next appointment.

Keep reading on this site

Sources checked

This article is published on The Global Ministerial Mental Health Summit site (GlobalMHSummit.com) by the GlobalMHSummit.com Research Team. It is for general educational purposes and is not medical advice. It does not diagnose, treat, or recommend any product. See our Medical Disclaimer and Editorial Standards.

NeuroLift: How to Use It, Price, Safety & Legitimacy

by

NeuroLift is a real supplement sold through an online checkout, but you should not rely on it as a proven fix for brain fog, focus, or memory. The practical answer on how to use it is simple: use only the directions on the bottle you receive, because the available NeuroLift information gives conflicting formula details and does not provide one dependable set of dosing instructions.

Affiliate disclosure: Links on this page may generate a commission if you buy through them.

Product Page

Quick answer

  • What it is: an online-sold supplement presented as NeuroLift.
  • How to use it: confirm the directions and Supplement Facts on the bottle before use.
  • Price: $49 to $79 per bottle, depending on the bundle.
  • Big decision point: the product materials do not give a settled, clearly matched formula and dose.

What is NeuroLift?

NeuroLift is an online-sold supplement offered in two-, three-, and six-bottle bundles. The checkout presents it as a one-time purchase, not an auto-ship plan. Its materials describe a 60-day satisfaction guarantee and order support by email and phone.

Do not confuse this product with other products and services that use the NeuroLift name. One Australian product called NeuroLift is a 60-tablet mood and thyroid-support formula, while another product uses the name for a multivitamin. Those are different products, so their directions, ingredients, and safety warnings do not tell you how to use the NeuroLift sold through this checkout.

How should you use NeuroLift?

There is no dependable public dosing instruction to repeat for this specific checkout product. One third-party listing describes one capsule daily, while the product materials also leave the serving size, amount per ingredient, and daily directions unsettled. That is too important to guess about, especially for a multi-ingredient supplement.

Use the current bottle label as the controlling instruction. If the bottle label is missing, unclear, or differs from what you expected, the seller’s support contact is care@aspensupps.com or 888-380-3133. A pharmacist or clinician can help assess a complete ingredient list alongside your medicines and health history.

What is in NeuroLift, and how is it supposed to work?

Product material names ginkgo biloba, phosphatidylserine, N-acetyl-L-carnitine, St. John’s wort, L-glutamine, bacopa monnieri, alpha-GPC, and huperzine-A. Other NeuroLift material describes a different blend involving B vitamins, caffeine from green coffee bean, L-tyrosine, theacrine, theobromine, bacopa, rhodiola, and Huperzia serrata. That mismatch matters: without the current Supplement Facts panel, you cannot know which formula, amounts, or stimulant exposure applies to your bottle.

For a plain-language breakdown of several commonly promoted cognitive ingredients, see NeuroLift ingredients. Our fuller guide, all eight ingredients, explains why ingredient amounts matter as much as ingredient names.

L-tyrosine is an amino acid your body uses to make chemicals involved in brain signaling. A small double-blind study in healthy young adults found better performance on a demanding working-memory task after a 2-gram tyrosine dose, but that study does not establish that NeuroLift produces the same result, particularly when its tyrosine amount is not stated. Read the tyrosine study for its design and limits.

Does NeuroLift really work for brain fog, focus, or memory?

There is no finished-product clinical result here that shows NeuroLift improves memory, focus, or brain fog. A supplement with familiar ingredients is not automatically a supplement with proven results, because the dose, combination, and the people studied all matter.

More broadly, Harvard Health reports that brain-health supplements have not shown solid proof that they improve thinking or prevent memory loss. Its discussion also notes that a large trial of ginkgo biloba did not lower dementia rates in older adults. See Harvard Health’s supplement guide for that context.

If poor focus or fuzzy thinking is new, persistent, or getting in the way of daily life, a clinician can help look at common contributors such as sleep, mood, medication effects, or physical health concerns. A supplement should not substitute for that conversation.

Who should be especially careful?

Be cautious with any bottle that lists St. John’s wort, caffeine, huperzine-A, or multiple stimulant-like ingredients. The seller’s terms say people who are pregnant, nursing, taking medication, or managing a medical condition should consult a physician before use. This is particularly relevant because St. John’s wort is named in one formula description and is known on another NeuroLift product label to affect many prescription medicines.

Situation Why the label matters
You take prescription medicine The exact formula may include ingredients with interaction concerns, including St. John’s wort.
You are sensitive to caffeine or stimulants One formula description includes caffeine, theacrine, and theobromine, but it does not state their individual amounts.
You are pregnant, nursing, or managing a condition The seller’s terms recommend speaking with a physician before use.
You have new or worsening memory changes A supplement purchase is not a diagnosis or treatment plan.

Is NeuroLift FDA approved?

No dietary supplement should be treated as FDA-approved for improving memory or focus. The checkout says NeuroLift is made in the United States in what the seller describes as a GMP-certified, FDA-registered facility; the FDA does not approve manufacturing facilities, and that statement is not approval of the product or proof that it works.

How much does NeuroLift cost?

Prices shown as of October 5, 2026; check the checkout for today’s price and taxes.

Package Listed supply Listed price Shipping
2 bottles 60 days $158 total ($79 per bottle) $19.99
3 bottles 90 days $207 total ($69 per bottle) Free
6 bottles 180 days $294 total ($49 per bottle) Free

The seller displays promotional savings and calls the six-bottle option its best value. That bundle has the lowest listed per-bottle price, but it also commits you to the largest upfront payment before you have confirmed that the label and directions suit you.

Where can you buy it, cancel, or request a refund?

NeuroLift is sold through the online checkout linked above. The seller says orders ship from a U.S. warehouse and are presented as one-time payments. Its terms say cancellation may be possible within 24 hours, before processing or shipment.

The seller describes a 60-day guarantee from the shipping date. For a refund, its terms say you first contact support, then return the bottles with the requested order information. The seller says return postage is your responsibility and that a refund is issued after the return is received and processed. It lists its return address in its return instructions; do not send a return before getting the seller’s current authorization and address.

Before you order

  • Confirm the current bottle’s Supplement Facts panel, serving size, and daily directions.
  • Check whether the formula contains St. John’s wort, caffeine, or other stimulants that matter for you.
  • Read the return instructions before choosing a multi-bottle bundle.
  • Keep your order confirmation, because the seller says it contains information needed for support and returns.
  • Treat sales-page ratings and urgency messages as promotional information, not a substitute for product-specific clinical results.

By GlobalMHSummit.com Research Team